» Articles » PMID: 22739622

Targeted Disruption of Organic Cation Transporter 3 (Oct3) Ameliorates Ischemic Brain Damage Through Modulating Histamine and Regulatory T Cells

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The organic cation transporters OCT1, 2, and 3 (SLC22A1-3) have been implicated in the elimination of biogenic amines such as histamine. Among them, OCT3 was identified as an uptake-2 transporter, responsible for clearance of histamine. Because increasing evidence suggests the involvement of histamine in cerebral ischemia, we investigated the effects of targeted disruption of organic cation transporter-3 (Oct3) on the severity of ischemic brain damage. Transient focal ischemia for 1 hour was induced by occlusion of the middle cerebral artery (MCA) of homozygous Oct3-deficient mice and their wild-type (Wt) littermates. Although targeted disruption of Oct3 did not affect physiological parameters after MCA occlusion, this disruption significantly increased histamine content in the ischemic cortex and significantly reduced the infarct volume after cerebral ischemia. Furthermore, targeted disruption of Oct3 prevented the reduction of regulatory T-cell proportion after cerebral ischemia while this disruption did not affect Th1 and Th2 cells proportions after ischemia. Since repeated administration of L-histidine (a precursor of histamine) to Wt mice also showed the same effects, our observations suggested that OCT3 is the molecule responsible for clearance of ischemia-induced histamine in the brain and targeted disruption of Oct3 ameliorated ischemic brain damage through an increase in regulatory T cells.

Citing Articles

Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets.

Jin B, Pang X, Zang Q, Ga M, Xu J, Luo Z Acta Pharm Sin B. 2023; 13(4):1699-1710.

PMID: 37139420 PMC: 10149982. DOI: 10.1016/j.apsb.2022.11.011.


.

Yee S, Giacomini K Drug Metab Dispos. 2021; 50(9).

PMID: 34921098 PMC: 9488978. DOI: 10.1124/dmd.121.000702.


Organic Cation Transporter Expression and Function in the CNS.

Sweet D Handb Exp Pharmacol. 2021; 266:41-80.

PMID: 33963461 DOI: 10.1007/164_2021_463.


Organic Cation Transporters in Brain Histamine Clearance: Physiological and Psychiatric Implications.

Naganuma F, Yoshikawa T Handb Exp Pharmacol. 2021; 266:169-185.

PMID: 33641029 DOI: 10.1007/164_2021_447.


The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy.

Yamauchi K, Ogasawara M Int J Mol Sci. 2019; 20(7).

PMID: 30965592 PMC: 6480561. DOI: 10.3390/ijms20071733.


References
1.
Maeda K, Hata R, Hossmann K . Differences in the cerebrovascular anatomy of C57black/6 and SV129 mice. Neuroreport. 1998; 9(7):1317-9. DOI: 10.1097/00001756-199805110-00012. View

2.
Akdis C, Akdis M . Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011; 127(1):18-27. DOI: 10.1016/j.jaci.2010.11.030. View

3.
Adachi N, Itoh Y, Oishi R, Saeki K . Direct evidence for increased continuous histamine release in the striatum of conscious freely moving rats produced by middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1992; 12(3):477-83. DOI: 10.1038/jcbfm.1992.65. View

4.
Doyle K, Simon R, Stenzel-Poore M . Mechanisms of ischemic brain damage. Neuropharmacology. 2008; 55(3):310-8. PMC: 2603601. DOI: 10.1016/j.neuropharm.2008.01.005. View

5.
Denes A, Thornton P, Rothwell N, Allan S . Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun. 2009; 24(5):708-23. DOI: 10.1016/j.bbi.2009.09.010. View